The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).
 
Rika Saito
No Relationships to Disclose
 
Yasuyuki Kawamoto
Honoraria - Lilly; Merck; Taiho Pharmaceutical
Research Funding - Japan Agency for Medical Research and Development
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Medical & Biological Laboratories; Merck; MSD K.K; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Susumu Sogabe
No Relationships to Disclose
 
Masayoshi Dazai
No Relationships to Disclose
 
Ayumu Hosokawa
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Teijin Pharma
Research Funding - Chugai Pharma (Inst); Eisai (Inst); Hisamitsu Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Kentaro Sawada
No Relationships to Disclose
 
Atsushi Sato
Honoraria - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Michio Nakamura
Honoraria - Asahi Kasei; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Takeda (Inst); Zeria Pharmaceutical (Inst)
 
Kazuteru Hatanaka
No Relationships to Disclose
 
Atsushi Ishiguro
No Relationships to Disclose
 
Osamu Muto
No Relationships to Disclose
 
Yoshiaki Shindo
No Relationships to Disclose
 
Yasushi Tsuji
Honoraria - Asahi Kasei; Bayer; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Sawai Pharmaceutical Co; Taiho Pharmaceutical
 
Miki Tateyama
No Relationships to Disclose
 
Akira Ueda
No Relationships to Disclose
 
Takahide Sasaki
No Relationships to Disclose
 
Masaki Katagiri
No Relationships to Disclose
 
Naoya Sakamoto
No Relationships to Disclose
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha